Multiple barriers exist in developing effective chimeric antigen receptor (CAR) T-cell therapies for solid tumors. Weijia Fang, MD, Zhejiang University, Hangzhou, China, describes strategies to improve the technology and control potential adverse events such as cytokine release syndrome (CRS). Novel variations of CAR T-cells such as chimeric autoantibody receptor T cells (CAART), mesothelin-specific CAR T-cell therapy, bispecific antibodies, NKG2D and EpCAM-targeting CAR T-cell therapy may provide promising responses in solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
